Ultragenyx Pharmaceutical Inc. (0LIF) Short Interest
LSE • 0LIF • US90400D1081
As of Nov 3, 2026, ORTEX estimates 3.4% of free float is sold short, 366.5 days to cover, cost to borrow 0.42%.
LSE • 0LIF • US90400D1081
As of Nov 3, 2026, ORTEX estimates 3.4% of free float is sold short, 366.5 days to cover, cost to borrow 0.42%.
This page tracks how heavily Ultragenyx Pharmaceutical Inc. (LSE:0LIF) is being shorted: ORTEX's daily short interest estimate, the cost to borrow the shares, utilization of the lendable supply and days to cover, next to the official exchange-reported figure.
Source: ORTEX. Some figures are limited on the free view; live data and full history are part of ORTEX Advanced.
Ultragenyx Pharmaceutical Inc. (LSE: 0LIF) has a market capitalization of $1.69B. Last close $17.50 (as of 2026-11-05); 52-week range $12.87 to $41.50. ORTEX data as of 2026-11-03: short interest is 3.38% of free float, 366.5 days to cover and the average cost to borrow is 0.42%.